Bremelanotide (PT-141) listed among compounds entering clinical trials in comprehensive drug-development survey
Background
Clinical drug development involves tracking hundreds of investigational compounds simultaneously across diverse disease areas, from oncology and cardiovascular disease to sexual dysfunction and infectious disease. Prous Science Integrity serves as a curated knowledge portal aggregating trial data to help researchers identify which agents are actively progressing through clinical evaluation. Bremelanotide (PT-141) is a cyclic heptapeptide MC1R/MC4R melanocortin receptor agonist originally investigated for sexual dysfunction, representing a peptide-based approach to a condition where approved pharmacological options remain limited. Tracking its clinical status alongside a wide array of small molecules and biologics contextualizes the competitive landscape for peptide therapeutics at the time of publication.
Study Design
The digest compiled and tabulated clinical trial data retrieved from the Prous Science Integrity Clinical Trials Knowledge Area database. No experimental intervention, animal model, patient cohort, or primary endpoint is described — this is a registry-style literature and congress survey. Bremelanotide is listed as one of over 100 compounds included in the current issue's selection. No dosing, route, frequency, duration, or control arm information is provided in the abstract.
Results
The abstract functions as a compound index rather than a results-reporting document; no quantitative outcomes, p-values, fold-changes, or efficacy data are presented for any listed agent including bremelanotide.
No numerical findings are reported in this abstract — the paper is a clinical-trials tracking digest, not a primary or secondary research study.
Bremelanotide's inclusion confirms it held active clinical trial status at the time of publication. The digest spans oncology agents (e.g., bevacizumab, panitumumab, ixabepilone), cardiovascular drugs (aliskiren fumarate, eplerenone, prasugrel), CNS compounds (iloperidone, paliperidone palmitate, pregabalin), anti-infectives (telavancin, iclaprim, linezolid), and peptide/biologic agents (ghrelin (human), pegfilgrastim, albinterferon alfa-2b), indicating a cross-therapeutic snapshot. No mechanistic, pharmacokinetic, or safety data are extractable from this source.
Key Findings
- Bremelanotide (PT-141) listed as an active clinical-trial compound in the Prous Science Integrity database.
- Over 100 investigational drugs catalogued across oncology, CNS, cardiovascular, anti-infective, and other areas.
- No quantitative efficacy, safety, or pharmacokinetic data provided for any listed compound.
- Data sourced from Prous Science Integrity clinical trials knowledge portal (http://integrity.prous.com).
Why It Matters
Bremelanotide's appearance in a multi-compound clinical-trials digest places it on the map of agents that had sufficiently advanced development programs to warrant monitoring by major drug-intelligence platforms. For clinicians and researchers tracking peptide therapeutics for sexual dysfunction, this type of registry entry marks a meaningful milestone in the compound's path toward regulatory review. The absence of efficacy or safety data here means no protocol or dosing guidance can be drawn from this specific source — practitioners must consult primary trial publications. From a landscape perspective, PT-141's co-listing alongside oncology biologics and small-molecule cardiovascular drugs underscores the breadth of the melanocortin-receptor peptide class relative to mainstream pharmaceutical pipelines at this developmental stage.
TitrateLab articles covering PT-141
Written by TitrateLab, separately from the study summarized above.
